Nabriva patents expiration
1. Xenleta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6753445 | NABRIVA | Pleuromutilin derivatives having antibacterial activity |
Jul, 2021
(2 years ago) | |
| US8153689 | NABRIVA | Pleuromutilin derivatives for the treatment of diseases mediated by microbes |
Mar, 2028
(3 years from now) | |
| US8071643 | NABRIVA | Pleuromutilin derivatives for the treatment of diseases mediated by microbes |
Jan, 2029
(4 years from now) | |
| US9120727 | NABRIVA | Process for the preparation of pleuromutilins |
May, 2031
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 19, 2024 |
| Generating Antibiotic Incentives Now(GAIN) | Aug 19, 2029 |
Drugs and Companies using LEFAMULIN ACETATE ingredient
NCE-1 date: 19 August, 2028
Market Authorisation Date: 19 August, 2019
Treatment: Treatment of adults with community-acquired bacterial pneumonia caused by susceptible microorganisms
Dosage: SOLUTION;INTRAVENOUS; TABLET;ORAL
More Information on Dosage
XENLETA family patents
